Compare Appian Corp (APPN) vs BioNano Genomics Inc (BNGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Appian Corp vs BioNano Genomics Inc — how do they compare? Appian Corp trades at $34.4 (market cap $2.54B), while BioNano Genomics Inc trades at $1.2 (market cap $13.66M). The key difference: Appian Corp is far larger — about 185.9× BioNano Genomics Inc's market cap, and Appian Corp is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| APPN | BNGO | |
|---|---|---|
Market Cap | $2.54B | $13.66M |
Sector | Technology | Health |
52-Week High | $45.64 | $4.92 |
52-Week Low | $18.72 | $1.06 |
Enterprise Value | $2.67B | $16.26M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Appian (APPN) trades at $34.42, down 3.26% on the day, following recent earnings beats but amid broader software stock volatility. The stock shows a bullish technical trend with moving averages supporting upside, though oscillators indicate overbought conditions. Fundamentally, revenue growth remains strong with 2025 revenue at $726.94 million and a return to positive net income of $1.23 million, yet profitability metrics like ROE at -936.62% highlight ongoing challenges. Recent news highlights AI-driven partnerships and enterprise demand as key growth catalysts.
The outlook is mixed: analyst consensus is cautious with a hold-heavy rating (63.16% hold) and a $32.50 price target below the current price, signaling limited near-term upside. Risks include high debt levels, negative equity, and competitive pressures in low-code software. Investment appeal hinges on sustained AI adoption and margin improvement, but volatility and weak shareholder equity pose significant risks.
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Appian Corp
Appian Corp provides a low-code software development platform as a service that enables organizations to rapidly develop powerful and unique applications. With its platform, organizations can rapidly and easily design, build and implement powerful, enterprise-grade custom applications through intuitive, visual interface with little or no coding required. The company's customers use applications built on its low-code platform to launch new business lines, automate vital employee workflows, manage complex trading platforms, accelerate drug development and build procurement systems. The group generates a majority of its revenue from the domestic market. It serves various industries such as education.
Read more on APPN →About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →
